Table 2 Comparison of characteristics of Persistent BSIs and No persistent BSIs
Persistent (n = 45) | No persistent BSI (n = 519) | P value | |
|---|---|---|---|
Age, median (IQR) | 60 (46–74) | 64 (55–76) | 0.130 |
Male sex, n (%) | 25 (55.6) | 294 (56.69 | 0.887 |
CCI (n), median (IQR) | 4 (2–6) | 5 (3–7) | 0.152 |
SOFA, median (IQR) | 4 (1–8) | 4 (2–6) | 0.014 |
SIRS, median (IQR) | 2 (1–2) | 2 (1–3) | 0.493 |
ICU, n (%) | 22 (48.9) | 207 (39.9) | 0.238 |
Central venous catheter, n (%) | 29 (64.4) | 220 (42.4) | 0.004 |
Cardiac device, n (%) | 6 (13.3) | 40 (7.7) | 0.186 |
Prosthetic device, n (%) | 1 (2.2) | 22 (4.2) | 0.512 |
Hospital-acquired BSI, n (%) | 33 (73.3) | 297 (57.2) | 0.035 |
Primary BSI, n (%) | 16 (35.6) | 228 (43.9) | 0.277 |
Secondary BSI, n (%) | 29 (64.4) | 291 (56.1) | |
Fermenter GN*, n (%) | 20 (44.4) | 362 (69.7) | 0.001 |
Non-fermenter GN**, n (%) | 25 (55.6) | 157 (30.3) | |
CR-GN, n (%) | 16 (48.5) | 114 (23.7) | 0.002 |
MDR, n (%) | 35 (77.8) | 356 (68.6) | 0.200 |
XDR, n (%) | 10 (22.2) | 66 (12.7) | 0.073 |
PDR, n (%) | 1 (2.2) | 5 (1.0) | 0.430 |
Appropriate empirical antibiotic therapy, n (%) | 10 (22.2) | 307 (59.2) | < 0.001 |